FDA finalizes guidance on requesting post-warning letter meetings
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionChemistry, Manufacturing and Controls (CMC)GenericsGMPQuality Assurance and ControlUnited StatesUS Food and Drug Administration (FDA)